President Trump to Announce Nationwide Medicaid Drug Pricing Model
President Trump is set to announce that all 50 U.S. states will participate in a Medicaid drug pricing model designed to lower the net price of selected drugs.
Lubbock, TX, September 18, 2026 —
President Donald Trump is reportedly preparing to announce the participation of all 50 U.S. states in a new Medicaid drug pricing model. This initiative is designed with the stated goal of reducing the net price paid for specific prescription drugs.
Details regarding the specific timeline for the announcement or the commencement of the program were not immediately available. The exact nature of the pricing model and which drugs will be subject to its provisions have also not been fully disclosed. The initiative aims to leverage the collective purchasing power of states within the Medicaid program to negotiate lower prices for pharmaceuticals.
The scope of the program encompasses all 50 states, indicating a broad federal effort to influence drug costs within the Medicaid system. The focus is on the “net price,” which typically refers to the price paid after rebates and other discounts are accounted for. This approach suggests a strategy to ensure greater transparency and potentially lower out-of-pocket costs for the government and beneficiaries.
Further information is expected to be released regarding the mechanisms by which the net price will be determined and enforced, as well as the specific criteria for selecting the drugs that will fall under this new pricing model. The contractor responsible for managing or implementing aspects of this model, if any, has not been identified. The expected announcement marks a significant step in the administration’s ongoing efforts to address prescription drug pricing in the United States.
Story summarized from the original created by FATIMA HUSSEIN, Associated Press on www.everythinglubbock.com, see more information here.
Media gallery
